X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.globenewswire.com/news-release/2024/04/06/2858812/0/en/New-Novartis-data-show-early-addition-of-twice-yearly-Leqvio-inclisiran-following-maximally-tolerated-statin-therapy-significantly-reduces-LDL-C-in-ASCVD-patients-in-real-world-set.html
https://www.prnewswire.com/news-releases/novartis-presents-new-long-term-leqvio-inclisiran-data-demonstrating-consistent-efficacy-and-safety-beyond-six-years-301910740.html
https://www.europeanpharmaceuticalreview.com/news/186102/sirna-therapy-inclisiran-shows-long-term-potential-in-lowering-ldl-c/
https://www.prnewswire.com/news-releases/us-fda-approves-expanded-indication-for-novartis-leqvio-inclisiran-to-include-treatment-of-adults-with-high-ldl-c-and-who-are-at-increased-risk-of-heart-disease-301872495.html
https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-will-not-move-forward-with-uk-anti-cholesterol-drug-trial-2023-03-22/
https://www.globenewswire.com/news-release/2022/11/07/2550290/0/en/New-long-term-Leqvio-inclisiran-data-from-Novartis-show-sustained-efficacy-and-safety-over-four-years.html
https://www.fiercepharma.com/pharma/fewer-doses-could-be-ticket-for-novartis-cholesterol-lowering-leqvio-which-could-pull-2-5
https://www.biopharmadive.com/news/novartis-leqvio-inclisiran-fda-approval-cholesterol-heart/611170/
https://www.globenewswire.com/news-release/2021/12/22/2357041/0/en/FDA-approves-Novartis-Leqvio-inclisiran-first-in-class-siRNA-to-lower-cholesterol-and-keep-it-low-with-two-doses-a-year.html
https://www.fiercepharma.com/pharma/amgen-s-otezla-repatha-and-biosimilars-put-notice-challenging-years-ahead
https://www.fiercepharma.com/pharma/where-will-novartis-spend-21b-from-roche-stake-sale-alnylam-could-be-one-report
https://endpts.com/novartis-touts-more-late-stage-data-for-inclisiran-the-once-centerpiece-heart-drug-spurned-by-the-fda/
https://www.europeanpharmaceuticalreview.com/news/161845/nice-approves-inclisiran-for-ldl-cholesterol-reduction/
https://psnc.org.uk/our-news/inclisiran-leqvio-added-to-a-new-section-in-the-drug-tariff-part-viiic/
https://www.fiercepharma.com/pharma/icer-outlines-cost-effective-price-range-for-pcsk9-cholesterol-drug-inclisiran-should
https://www.biopharmadive.com/news/icer-inclisiran-cholesterol-cost-novartis/593819/
https://www.fiercepharma.com/pharma/novartis-sets-date-for-inclisiran-crl-response-but-what-about-fda-approval-timeline
https://endpts.com/novartis-9-7b-pcsk9-drug-nabs-first-ok-now-comes-the-challenge-of-finding-a-market/
https://www.reuters.com/article/novartis-cholesterol/novartis-gets-eu-approval-for-potential-blockbuster-cholesterol-drug-leqvio-idUSKBN28L0JL
https://www.fiercepharma.com/marketing/novartis-9-7b-medco-buyout-bears-first-fruit-as-blockbuster-to-be-inclisiran-nabs-eu-nod
https://www.reuters.com/article/us-novartis-cholesterol/novartis-sees-eu-ok-ahead-after-panel-nod-for-10-bln-anti-cholesterol-prospect-idUSKBN2712BL
https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-leqvio-inclisiran-potential-first-class-sirna-treatment-high-cholesterol
https://www.fiercepharma.com/pharma/esc-amgen-chases-pediatric-use-for-cholesterol-busting-pcsk9-med-repatha
https://endpts.com/new-analysis-shows-inclisiran-consistency-in-ldl-c-reduction-as-novartis-readies-for-fda-decision/
https://www.prnewswire.com/news-releases/novartis-new-analysis-shows-high-consistency-in-lowering-ldl-c-in-individual-response-with-investigational-inclisiran-301120583.html
https://icer-review.org/announcements/icer-to-assess-treatments-for-high-cholesterol/
https://www.fiercebiotech.com/biotech/novartis-cholesterol-buster-new-trial-starts-fall-victim-to-pandemic-report
https://www.fiercebiotech.com/biotech/acc-new-owner-novartis-presents-pooled-inclisiran-data-cutting-ldl-cholesterol-by-half
https://www.prnewswire.com/news-releases/novartis-announces-nejm-publication-of-three-pivotal-trials-showing-durable-and-potent-efficacy-of-inclisiran-an-investigational-first-in-class-sirna-cholesterol-lowering-therapy-301026481.html
http://www.pmlive.com/pharma_news/novartis_picks_up_inclisiran_after_completion_of_medco_acquisition_1321708
https://www.biospace.com/article/the-medicines-company-s-inclisiran-positive-in-2-phase-iii-cholesterol-trials/?s=95
https://www.fiercebiotech.com/biotech/its-last-phase-3-bag-med-co-s-inclisiran-poised-for-pcsk9-battle
https://endpts.com/medco-builds-its-case-for-star-cholesterol-rnai-therapy-with-two-new-positive-pivotal-studies/
https://www.fiercebiotech.com/biotech/clean-safety-and-efficacy-data-tee-medicines-company-up-for-pcsk9-scrap
https://www.biospace.com/article/u-s-district-court-invalidates-amgen-patents-over-cholesterol-med/
https://www.biopharmadive.com/news/medicines-company-inclisiran-orion-11-pcsk9-ldl-cholesterol/561667/
https://www.fiercepharma.com/marketing/amgen-s-sanofi-s-already-lackluster-pcsk9-drugs-could-be-under-major-threat-analyst
https://endpts.com/analysis-shows-the-medicines-company-alnylam-drug-inclisiran-safe-for-renally-impaired-patients/
https://www.fiercebiotech.com/biotech/long-term-data-med-co-alnylam-s-cholesterol-fighter-inclisiran-poised-for-2019-filing
Market Place
Share 
